Drug Profile
Hydromorphone extended release - Teva Pharmaceutical Industries
Alternative Names: CEP-33236Latest Information Update: 08 Oct 2021
Price :
$50
*
At a glance
- Originator Cephalon
- Developer Teva Pharmaceutical Industries
- Class Morphine derivatives; Opioid analgesics; Small molecules
- Mechanism of Action Opioid receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Pain
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Pain in USA (PO, Controlled release)
- 31 Dec 2009 Phase-I clinical trials in Pain in USA (PO)